Has Edith Garneau, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,879 in general payments to Edith Garneau, MD across 538 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edith Garneau, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edith Garneau, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edith Garneau, MD

Rheumatology · Brockton, MANPI 1407085558

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 538 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 29.7% of the total. 2025 is the largest year on record at $3,130, 2.6 times the $1,213 reported in 2019.

$10,879in general payments, 2019–2025

Across 538 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Amgen$2K
Johnson & Johnson$1K
Lilly USA, LLC$689
UCB, Inc.$656
Mallinckrodt Hospital Products Inc.$529
plus $3K from 23 others

What the payments were for

Food & beverage$10,56497%
Education$3143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	159	$3,228
Amgen(2 entities)	101	$2,102
Johnson & Johnson	46	$1,051
Lilly USA, LLC	39	$689
UCB, Inc.	44	$656
Mallinckrodt Hospital Products Inc.	25	$529
GSK	27	$492
E.r. Squibb & Sons, L.L.C.	17	$333
Novartis	9	$272
Genentech USA, Inc.	8	$229
Pfizer	9	$166
AstraZeneca(2 entities)	9	$163
Sandoz	5	$129
Organon	6	$127
ANI Pharmaceuticals, Inc.	5	$126
Sanofi	3	$95
Boehringer Ingelheim	4	$84
Sobi, Inc	4	$82
Hikma Pharmaceuticals USA	5	$80
Fresenius Kabi USA, LLC	2	$41
Novo Nordisk	2	$40
Regeneron Healthcare Solutions, Inc.	2	$37
Mylan Pharmaceuticals Inc.	1	$23
Medtronic	1	$21
Bristol Myers Squibb	1	$21
Corcept Therapeutics	1	$16
Xeris Pharmaceuticals, Inc.	1	$16
Kowa Pharmaceuticals America, Inc.	1	$16
Mallinckrodt Enterprises LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,879 in reported general payments places this provider in the 75th percentile of 265 rheumatology providers in Massachusetts.

See all rheumatology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$671,668

Medicare patients

237

Services billed

30,685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	26	$191,674
Orencia ClickjectAbatacept	16	$88,585
Actemra ActpenTocilizumab	13	$43,935
Hydroxychloroquine Sulfate	270	$11,003
MethotrexateMethotrexate Sodium	192	$5,382
Colchicine	18	$2,909
Leflunomide	29	$1,951
Diclofenac Sodium	24	$1,886
Febuxostat	13	$1,853
Duloxetine Hcl	47	$1,826
Prednisone	234	$1,552
Leucovorin Calcium	54	$893
Gabapentin	131	$872
Sulfasalazine	34	$834
Tramadol Hcl	179	$807

Paid to pharmacies, not to this prescriber.

Other rheumatology in Brockton

Raphael KievalBrockton$146K
Marilyn PikeBoston$1.4M
John StoneBoston$926K
Lee SimonBoston$600K
Jeffrey SparksBoston$299K
Ronald RapoportFall River$293K
Richard ChouPalmer$270K
Tanya LaidlawBoston$244K
Tuhina NeogiBoston$242K
Michael WeinblattBoston$228K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →